Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00109863|
Recruitment Status : Completed
First Posted : May 4, 2005
Last Update Posted : February 16, 2015
RATIONALE: Biological therapies, such as hu14.18-interleukin-2 fusion protein, may stimulate the immune system in different ways and stop tumor cells from growing.
PURPOSE: This phase II trial is studying how well hu14.18-interleukin-2 fusion protein works in treating patients with advanced melanoma.
|Condition or disease||Intervention/treatment||Phase|
|Melanoma (Skin)||Biological: hu14.18-IL2 fusion protein||Phase 2|
- Determine the clinical antitumor activity of hu14.18-interleukin-2 fusion protein in patients with advanced melanoma.
- Determine the duration of response in patients treated with this drug.
- Determine the adverse events in patients treated with this drug.
- Determine the in vivo immunologic activation in patients treated with this drug.
- Determine the induction of anti-hu14.18 and anti-interleukin-2 antibodies in patients treated with this drug.
- Determine tumor antigen recognition by this drug in select patients with cutaneous metastatic tumors, as measured by binding of the drug to the cutaneous metastatic tumor and microscopic changes (including immune cell density and phenotype) of the tumor tissue.
OUTLINE: Patients receive hu14.18-interleukin-2 fusion protein IV over 4 hours on days 1-3. Treatment repeats every 28 days for 2 courses in the absence of symptomatic disease progression or unacceptable toxicity. Patients then undergo disease reassessment. Patients with an objective partial or complete clinical response or stable disease receive 2 additional courses of treatment.
PROJECTED ACCRUAL: A total of 14-30 patients will be accrued for this study within 7-15 months.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||14 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Trial of Hu14.18-IL2 (EMD 273063) in Subjects With Advanced Melanoma|
|Study Start Date :||May 2005|
|Actual Primary Completion Date :||July 2007|
|Actual Study Completion Date :||February 2014|
Experimental: Hu14.18-IL2 Treatment
Hu14.18-IL2 will be given on days 1, 2, and 3 of each course of therapy as a 4 hour continuous IV infusion at a daily dose of 6 mg/m2. Treatment courses will be repeated every 28 days at the same dose.
Biological: hu14.18-IL2 fusion protein
- Objective response rate and duration of response by clinical exam and radiology studies after every 2 courses
- Adverse events by clinical assessment daily during treatment and weekly after completion of study treatment
- Immunologic activation induced by hu14.18-interleukin-2 after every 2 courses
- Induction of anti-idiotypic antibodies on days 1, 3, 4, and 8 of each course
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00109863
|United States, Wisconsin|
|University of Wisconsin Paul P. Carbone Comprehensive Cancer Center|
|Madison, Wisconsin, United States, 53792-6164|
|Study Chair:||Mark R. Albertini, MD||University of Wisconsin, Madison|